Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1666089

registered interest
date	19/10/2023
answering body	Department for Science, Innovation and Technology
answering dept id	216
answering dept short name	Science, Innovation and Technology
answering dept sort name	Science, Innovation and Technology
hansard heading	Cybercrime: Small Businesses
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Science, Innovation and Technology, what recent assessment she has made with Cabinet colleagues on the potential vulnerability of SMEs to cyber-attacks.
tabling member constituency	Barnsley Central
tabling member printed	Dan Jarvis
uin	203492
answer	answer is ministerial correction date of answer 25/10/2023 answer text <p>The 2023 <a href="https://www.gov.uk/government/statistics/cyber-security-breaches-survey-2023" target="_blank">Cyber Security Breaches Survey</a> shows 32% of small businesses and 31% of micro businesses identified having suffered a cyber breach or attack in the past 12 months. This is a decline on 2022, however we believe this may be due to smaller businesses deprioritising cyber security and being less likely to identify breaches and attacks, rather than a reduction in the threat.</p><p>Our strategy, working with other relevant Departments and Agencies, is therefore to make it as easy as possible for SMEs to be secure.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 25/10/2023 15:39:09 answering member 4020 label Biography information for George Freeman
tabling member	4243 label Biography information for Dan Jarvis

1541804

registered interest
date	14/11/2022
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Research: Finance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, whether he has made a recent assessment of the potential merits of public sector funding for research and development; and if he will make an assessment of that funding on private sector investment in research and development at all stages of research.
tabling member constituency	Barnsley Central
tabling member printed	Dan Jarvis
uin	86489
answer	answer is ministerial correction date of answer 18/11/2022 answer text <p>BEIS has published research by Oxford Economics on the relationship between public and private funding of research and development (R&amp;D) at which estimated the monetary impact of the long-run leverage rate, suggesting that each £1 of public R&amp;D eventually stimulates between £1.96 and £2.34 of private R&amp;D:</p><p><a href="https://www.gov.uk/government/publications/research-and-development-relationship-between-public-and-private-funding" target="_blank">https://www.gov.uk/government/publications/research-and-development-relationship-between-public-and-private-funding</a>.</p><p> </p><p>Public investment in R&amp;D underpins long-term economic growth, is a vital component in our plan for achieving Net Zero and ensures the long-term defence and security of the UK by keeping us at the forefront of technological capabilities. This is why, at the last Spending Review, the Government announced the largest ever sustained uplift in public R&amp;D spending.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 18/11/2022 09:26:21 answering member 4020 label Biography information for George Freeman previous answer version 35259 answering member constituency Mid Norfolk answering member printed George Freeman answering member 4020 label Biography information for George Freeman
tabling member	4243 label Biography information for Dan Jarvis

1455226

registered interest
date	29/03/2022
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Research: South Yorkshire
house id	1
legislature	25259 pref label House of Commons
question text	What steps his Department is taking to support research and development in South Yorkshire as part of the Government’s levelling up agenda.
tabling member constituency	Barnsley Central
tabling member printed	Dan Jarvis
uin	906355
answer	answer is ministerial correction date of answer 29/03/2022 answer text <p>We are growing R&amp;D clusters around the country and I recently had the pleasure of visiting the BioYorkshire cluster. The Levelling Up White Paper set a new mission to increase domestic public investment in R&amp;D outside the Greater South East by at least one third over the Spending Review period and at least 40 percent by 2030.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 29/03/2022 11:56:26 answering member 4020 label Biography information for George Freeman
tabling member	4243 label Biography information for Dan Jarvis

383903

registered interest
date	18/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Everolimus: Finance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what plans he has to provide funding for everolimus.
tabling member constituency	Barnsley Central
tabling member printed	Dan Jarvis
uin	3075
answer	answer is ministerial correction date of answer 23/06/2015 answer text <p>It is for National Health Service commissioners to make funding decisions on individual treatments taking into account guidance from the National Institute for Health and Care Excellence (NICE) where available. Cancer drugs that are not routinely funded by the NHS may be available through the Cancer Drugs Fund.</p><p> </p><p> </p><p> </p><p>Everolimus is available through the Cancer Drugs Fund for two indications: (i) in combination with exemestane, for advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy and (ii) for the second-line treatment of advanced renal cell carcinoma.</p><p> </p><p> </p><p> </p><p>Everolimus is currently being appraised by NICE for the prevention of organ rejection in liver transplantation and for use in renal transplantation.</p><p> </p><p> </p><p> </p><p>Everolimus is also licensed for use in the treatment of Tuberous Sclerosis and Subependymal Giant Cell Astrocytoma (SEGA). NICE has not been asked to develop guidance on the use of everolimus for these conditions. It is therefore for NHS commissioners to take funding decisions based on an assessment of the available evidence.</p><p> </p><p> </p><p> </p><p>In January this year, NHS England launched a three-month public consultation to seek people’s views about proposals for a set of principles which NHS England should apply when making investment decisions and a new process for developing commissioning policies for specific treatments, drugs and medical devices. These elements are part of a Framework, which, when finalised, will underpin every decision NHS England makes about specialised services investments.</p><p> </p><p> </p><p> </p><p>Now that the consultation has ended, NHS England has advised that work is underway to determine whether any amendments are required to its proposals as a result of the feedback received.</p><p> </p><p> </p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 23/06/2015 10:15:27 answering member 4020 label Biography information for George Freeman
tabling member	4243 label Biography information for Dan Jarvis

170452

registered interest
date	15/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Drugs: Licensing
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what discussions he has had with clinicians about how to improve the uptake of clinically and cost-effective off-patent drugs outside their licensed indications.
tabling member constituency	Barnsley Central
tabling member printed	Dan Jarvis
uin	218685
answer	answer is ministerial correction date of answer 18/12/2014 answer text <p>We have had no detailed discussions but we are holding a roundtable stakeholder event in the new year where we will discuss a number of issues raised by the Off-Patent Drugs Bill. Individual prescribing decisions on the most appropriate treatments are a matter for clinicians, in discussion with their patients.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 18/12/2014 15:44:54 answering member 4020 label Biography information for George Freeman
tabling member	4243 label Biography information for Dan Jarvis

170453

registered interest
date	15/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Prescription Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will develop a strategy and workplan with targets for increasing the use of off-label medicines.
tabling member constituency	Barnsley Central
tabling member printed	Dan Jarvis
uin	218686
answer	answer is ministerial correction date of answer 18/12/2014 answer text <p>I refer the hon. Member to the answer I gave to the hon. Member for Crawley (Henry Smith) on 24 November 2014 to Question <a href="http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Commons/2014-11-17/214424/" target="_blank">214424</a></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 18/12/2014 15:49:03 answering member 4020 label Biography information for George Freeman
tabling member	4243 label Biography information for Dan Jarvis

170454

registered interest
date	15/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Breast Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what discussions he has had with the National Institute for Health and Care Excellence (NICE) associates network about how to remove barriers to implementing NICE familial breast cancer guidance on the use of tamoxifen and raloxifene for women at high risk of breast cancer.
tabling member constituency	Barnsley Central
tabling member printed	Dan Jarvis
uin	218687
answer	answer is ministerial correction date of answer 18/12/2014 answer text <p>The Department has asked the National Institute for Health and Care Excellence to seek feedback from its associates network about progress made in implementing the 2013 updated clinical guideline on prevention of familial breast cancer and for information about any challenges they have encountered with implementation.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 18/12/2014 17:37:27 answering member 4020 label Biography information for George Freeman
tabling member	4243 label Biography information for Dan Jarvis

100411

registered interest
date	22/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cystic Fibrosis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps the Government is taking to support research into new treatments for people with cystic fibrosis.
tabling member constituency	Barnsley Central
tabling member printed	Dan Jarvis
uin	211584
answer	answer is ministerial correction date of answer 27/10/2014 answer text <p>The National Institute for Health Research (NIHR) Evaluation, Trials and Studies Coordinating Centre manages the Efficacy and Mechanism Evaluation programme. With funding from the Medical Research Council, this programme is currently supporting a £3.3 million trial of repeated application of gene therapy in patients with cystic fibrosis. The report of this trial is expected to be published in August 2015.</p><p> </p><p><strong> </strong></p><p> </p><p>A range of commercial and researcher-led cystic fibrosis treatment trials and studies are hosted by NIHR research infrastructure including the NIHR Clinical Research Network, NIHR biomedical research centres and units, and NIHR clinical research facilities for experimental medicine.</p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 27/10/2014 16:52:12 answering member 4020 label Biography information for George Freeman
tabling member	4243 label Biography information for Dan Jarvis